# Antiviral & Antimicrobial Countermeasures Discovery and Development Core

> **NIH NIH UC7** · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · 2024 · $1,295,544

## Abstract

PROJECT ABSTRACT
 The proposed Antiviral & Antimicrobial Countermeasures Discovery & Development Core (herein
abbreviated as A2CD2C) will facilitate biomedical research targeted toward the discovery and/or development
of countermeasures for prophylactic or therapeutic treatment of human biosafety level 3 (BSL-3) pathogens or
BSL-2 pathogens that mandate select agent control. The A2CD2C will enable this research using state-of-the-art
equipment for small molecule (1) screening, (2) imaging, (3) liquid chromatography-mass spectrometry
(LCMS/MS) services and (4) histology. The core will be housed within the UTHSC Regional Biocontainment
Laboratory (RBL) in BSL-3 space. The A2CD2C is significant in that it provides an efficient, integrated,
comprehensive platform that will facilitate studies from the initial discovery phase through pre-clinical
development within BSL-3 containment. The A2CD2C is unique within the RBL network in its focus on providing
LC-MS studies for infected, treated animal tissues in BSL-3 to provide much needed information of the site of
exposure of the therapeutic at the site of infection and thereby providing important pharmacodynamic information
required for preclinical assessment.
 The major mission of the A2CD2C is to maintain, improve and expand our RBL support services in drug
discovery and development with a focus on drug pharmacodynamics in terms of how and how much drug
exposure impacts pathogen survival. We propose three objectives to achieve herein: Objective 1. To maintain
A2CD2C support services in drug discovery and development; Objective 2. To improve A2CD2C support services
in drug discovery and development; and Objective 3. To expand A2CD2C support services in imaging in drug
discovery and development.

## Key facts

- **NIH application ID:** 10910184
- **Project number:** 5UC7AI180313-02
- **Recipient organization:** UNIVERSITY OF TENNESSEE HEALTH SCI CTR
- **Principal Investigator:** Colleen B Jonsson
- **Activity code:** UC7 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,295,544
- **Award type:** 5
- **Project period:** 2023-08-18 → 2028-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10910184

## Citation

> US National Institutes of Health, RePORTER application 10910184, Antiviral & Antimicrobial Countermeasures Discovery and Development Core (5UC7AI180313-02). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10910184. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*